Registration Dossier

Administrative data

Description of key information

Sodium acrylate is virtually nontoxic after a single ingestion. 
Oral: LD50 > 5000 mg/kg bw (Wistar rat)

Key value for chemical safety assessment

Additional information

Oral exposure route:

 

In an acute toxicity study conducted by BASF AG (1986) groups of 2 and 5 rats per dose respectively were administered doses of 2000, 4000, and 5000 mg/kg bw by gavage and observed over a time period of 7 days for lethality and clinical signs of intoxication. The mortality rate was 0/2, 0/2, and 0/5 at 2000, 4000, and 5000 mg/kg bw, respectively. Thus, the LD50 was greater than 5000 mg/kg bw. No clinical signs of toxicity were observed at any dose level and no gross-pathological abnormalities were detected at necropsy of survivors. The mean body weight of groups increased at a normal rate during the observation period.

 

In two supporting studies, LD50 values of approx. 7000 and greater than 4000 mg/kg bw in rats were determined, respectively (BASF AG 1961, 1956).

 

 

Dermal exposure route:

There are no data available concerning the acute toxicity of sodium acrylate by the dermal exposure route.

In accordance with section 1.2 of REACH Annex XI, conduct of an acute dermal toxicity study is not justified as there is sufficient weight of evidence leading to the assumption that no acute dermal toxicity of the substance exists. Sodium acrylate is virtually nontoxic after a single ingestion with an oral LD50 > 5000 mg/kg bw in Wistar rats. Data on toxicokinetics and metabolism of the structural analogue acrylic acid via the oral and dermal routes showed that once the substance was systemically available, it was rapidly metabolized and eliminated from the body as either CO2in the expired air or urinary metabolites. No qualitative differences in urinary metabolites between routes were observed, indicating no marked route-dependent differences in the metabolic fate of AA. In addition, sodium acrylate does not possess any skin irritating properties that could lead to secondary toxicity. Thus, assuming 100 % dermal absorption as worst-case scenario, acute toxicity by the dermal route is not expected to be greater than toxicity by the oral route which was virtually non-existent. Hence, no further testing is required.

 

 

Inhalation exposure route:

 

Concerning the acute inhalation toxicity of sodium acrylate, no valid studies are available. Only an Inhalation Hazard Test was performed which is not a suitable test system for solid test substances.

In accordance with column 2 of REACH Annex VIII, no acute toxicity study by the inhalation route has to be conducted as exposure of humans via inhalation is not likely since the vapour pressure of the substance is extremely low.

 

 

Taking all the presented data into consideration, sodium acrylate was concluded to be virtually nontoxic after a single ingestion. Based on all the available information, acute toxicity of the substance after dermal application is not expected. Due to its extremely low vapour pressure, exposure by the inhalation route is not expected.

Justification for classification or non-classification

EU classification according to Annex VI of Directive 67/548/EEC: no classification required

GHS classification (GHS UN rev.3, 2009): no classification required